|
|
| Company History |
| Intas Biopharmaceuticals Limited launched its biotechnology operations in May 2000 comprising of Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) |
| Salient Features |
- R&D and Manufacturing facilities doubled within 4 years
- Human resources increased by a factor of 10 since inception
- EMEA approval obtained in just 3 years
- Therapeutic recombinant protein development from bench to commercial product in 3 years flat
|
| Starting with bio-generics, Intas Biopharma has structured its progression to the development of proprietary and innovative recombinant biopharmaceuticals. |
| The company has successfully launched therapeutic recombinant proteins Neukine® (rHu G–CSF), Erykine & Epofit (rHu EPO), Intalfa (rHu IFN Alfa-2b) and Neupeg™ (Pegylated rHu G-CSF), world’s first Peg Filgrastim after the innovator. |
| The company has also invested in one of the best cold chain packaging systems validated to maintain required conditions and ensure retention of product efficacy from plant to destination. |
| Milestones |
| Division Conceptualized |
May 2000 |
| First Clone/Technology acquired |
Aug 2001 |
| R&D centre operational |
Oct 2001 |
| Manufacturing Facility operational |
March 2003 |
| Neukine® (rHu G-CSF) launched |
July 2004 |
| Erykine & Epofit (rHu EPO) launched |
May 2005 |
| Intalfa (rHu IFN Alfa-2b) launched |
March 2007 |
| EU-GMP certification received |
March 2007 |
| Facility expansion |
March 2007 |
| Neupeg™ (Pegylated rHu G-CSF) launched |
October 2007 |
|
| |
|
| Contact |
|
 |
|
| Intas Biopharmaceuticals Ltd. |
Plot No. 423 / P / A/ GIDC
Sarkhej - Bavla Highway,
Moraiya,
Taluka - Sanand, 382 210
Ahmedabad, Gujarat
India. |
|
Telephone No. : +91 - 2717 - 660100/01
Fax : +91 - 2717 - 251189 |
|
| |
|